ATE251160T1 - Purin-derivative inhibitoren der tyrosi-protein kinase syk - Google Patents

Purin-derivative inhibitoren der tyrosi-protein kinase syk

Info

Publication number
ATE251160T1
ATE251160T1 AT00953112T AT00953112T ATE251160T1 AT E251160 T1 ATE251160 T1 AT E251160T1 AT 00953112 T AT00953112 T AT 00953112T AT 00953112 T AT00953112 T AT 00953112T AT E251160 T1 ATE251160 T1 AT E251160T1
Authority
AT
Austria
Prior art keywords
tyrosi
protein kinase
purine derivative
kinase syk
derivative inhibitors
Prior art date
Application number
AT00953112T
Other languages
English (en)
Inventor
Stephen Paul Collingwood
Judy Hayler
Grand Darren Mark Le
Henri Mattes
Keith Allan Menear
Clive Victor Walker
Xiao-Ling Novartis H Cockcroft
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE251160T1 publication Critical patent/ATE251160T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00953112T 1999-07-30 2000-07-28 Purin-derivative inhibitoren der tyrosi-protein kinase syk ATE251160T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918035.8A GB9918035D0 (en) 1999-07-30 1999-07-30 Organic compounds
PCT/EP2000/007311 WO2001009134A1 (en) 1999-07-30 2000-07-28 Purine derivatives inhibitors of tyrosine protein kinase syk

Publications (1)

Publication Number Publication Date
ATE251160T1 true ATE251160T1 (de) 2003-10-15

Family

ID=10858317

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00953112T ATE251160T1 (de) 1999-07-30 2000-07-28 Purin-derivative inhibitoren der tyrosi-protein kinase syk

Country Status (33)

Country Link
US (1) US6589950B1 (de)
EP (1) EP1200435B1 (de)
JP (2) JP2003506375A (de)
KR (1) KR100485289B1 (de)
CN (1) CN1213047C (de)
AR (1) AR029175A1 (de)
AT (1) ATE251160T1 (de)
AU (1) AU767349B2 (de)
BR (1) BR0012888A (de)
CA (1) CA2379560C (de)
CO (1) CO5180626A1 (de)
CZ (1) CZ2002299A3 (de)
DE (1) DE60005684T2 (de)
DK (1) DK1200435T3 (de)
EC (1) ECSP003589A (de)
ES (1) ES2208395T3 (de)
GB (1) GB9918035D0 (de)
HK (1) HK1046679A1 (de)
HU (1) HUP0201935A3 (de)
IL (1) IL147455A0 (de)
MX (1) MXPA02001102A (de)
MY (1) MY126862A (de)
NO (1) NO20020467L (de)
NZ (1) NZ516667A (de)
PE (1) PE20010543A1 (de)
PL (1) PL354477A1 (de)
PT (1) PT1200435E (de)
RU (1) RU2248977C2 (de)
SK (1) SK285730B6 (de)
TR (1) TR200200234T2 (de)
TW (2) TWI255268B (de)
WO (1) WO2001009134A1 (de)
ZA (1) ZA200200783B (de)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1941501A (en) * 1999-11-30 2001-06-12 Parker Hughes Institute Syk localized at centrosome
FR2802091A1 (fr) * 1999-12-08 2001-06-15 Oreal Compositions pour la teinture des fibres keratiniques contenant des derives de paraphenylenediamine a groupement azetidinyle
BR0114020A (pt) 2000-09-20 2003-07-22 Merck Patent Gmbh 4-amino-quinazolinas
KR100847169B1 (ko) 2000-12-21 2008-07-17 글락소 그룹 리미티드 혈관형성 조절제로서의 피리미딘아민
GB0101686D0 (en) * 2001-01-23 2001-03-07 Cancer Res Campaign Tech Cyclin dependent kinase inhibitors
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
EP1578722A4 (de) * 2001-10-12 2006-09-06 Irm Llc Kinaseinhibitorgerüste und verfahren zu deren herstellung
US20030158195A1 (en) 2001-12-21 2003-08-21 Cywin Charles L. 1,6 naphthyridines useful as inhibitors of SYK kinase
DE60320933D1 (de) * 2002-01-10 2008-06-26 Bayer Healthcare Ag Rho-kinase inhibitoren
CA2473910C (en) 2002-01-23 2011-03-15 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
EP1470121B1 (de) 2002-01-23 2012-07-11 Bayer HealthCare LLC Pyrimidin-derivate als rho kinase inhibitoren
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2306880T3 (es) 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv Derivados de sulfonilamino como inhibidores novedosos de la histona desacetilasa.
US7501417B2 (en) 2002-03-13 2009-03-10 Janssen Pharmaceutica, N.V. Aminocarbonyl-derivatives as novel inhibitors of histone deacetylase
US6897307B2 (en) 2002-03-28 2005-05-24 Novartis Ag Process for preparing 2,6-diaminopurine derivatives
US6855724B2 (en) 2002-04-08 2005-02-15 Agouron Pharmaceuticals, Inc. Tropane derivatives useful in therapy
EP1515955A4 (de) * 2002-06-17 2006-05-03 Smithkline Beecham Corp Chemisches verfahren
DE60325984D1 (de) * 2002-07-19 2009-03-12 Memory Pharmaceutical Corp 4-aminobenzofuranverbindungen als phosphodiesterase-4-inhibitoren
NZ537752A (en) 2002-07-29 2006-12-22 Rigel Pharmaceuticals Inc Use of 2,4-pyrimidinediamine compounds in the preparation of medicaments for treating autoimmune diseases
EP1444982A1 (de) * 2003-02-06 2004-08-11 Merckle Gmbh Verwendung von Purinderivaten als selektive Kinase-Inhibitoren
KR101201603B1 (ko) 2003-07-30 2012-11-14 리겔 파마슈티칼스, 인크. 자가면역 질환의 치료 또는 예방에 사용하기 위한2,4-피리미딘디아민 화합물
BRPI0413563A (pt) * 2003-08-15 2006-10-17 Irm Llc compostos e composições como inibidores de atividade do receptor de quìnase de tirosina
ES2361835T3 (es) * 2003-09-25 2011-06-22 Janssen Pharmaceutica Nv Derivados de purina inhibidores de la replicación del hiv.
CN1901903A (zh) * 2003-11-06 2007-01-24 细胞基因公司 用于治疗和控制石棉相关性疾病和病症的包含jnk抑制剂的组合物以及其使用方法
WO2005047524A2 (en) 2003-11-10 2005-05-26 The Scripps Research Institute Compositions and methods for inducing cell dedifferentiation
GB0407723D0 (en) * 2004-04-05 2004-05-12 Novartis Ag Organic compounds
US8057815B2 (en) * 2004-04-19 2011-11-15 Portola Pharmaceuticals, Inc. Methods of treatment with Syk inhibitors
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7626021B2 (en) * 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
BRPI0513916A (pt) * 2004-07-27 2008-05-20 Sgx Pharmaceuticals Inc moduladores de pirrol-piridina cinase
US7361764B2 (en) * 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
MX2007001126A (es) 2004-07-27 2007-09-25 Sgx Pharmaceuticals Inc Moduladores de heterociclo cinasa de anillo fusionado.
EP1781639B1 (de) * 2004-07-28 2012-01-25 Janssen Pharmaceutica NV Substituierte indolylalkylaminoderivate als neue inhibitoren von histondeacetylase
AU2005281735A1 (en) * 2004-09-10 2006-03-16 Nycomed Gmbh Ciclesonide and syk inhibitor combination and methods of use thereof
ATE540035T1 (de) 2004-11-24 2012-01-15 Rigel Pharmaceuticals Inc Spiro-2,4-pyrimidindiamin-verbindungen und ihre verwendungen
CN100526315C (zh) * 2005-06-16 2009-08-12 浙江医药股份有限公司新昌制药厂 N2-喹啉或异喹啉取代的嘌呤衍生物及其制备方法和其用途
EP1948658A1 (de) * 2005-10-13 2008-07-30 Glaxo Group Limited Pyrrolopyrimidinderivate als syk-inhibitoren
JP2009519218A (ja) * 2005-11-03 2009-05-14 エスジーエックス ファーマシューティカルズ、インコーポレイテッド ピリミジニル−チオフェンキナーゼモジュレータ
WO2007070872A1 (en) 2005-12-15 2007-06-21 Rigel Pharmaceuticals, Inc. Kinase inhibitors and their uses
EP1981874B1 (de) * 2006-01-19 2009-05-27 Janssen Pharmaceutica, N.V. Aminophenylderivate als neue inhibitoren von histondeacetylase
JP5247470B2 (ja) 2006-01-19 2013-07-24 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒストンデアセチラーゼのインヒビターとしてのピリジン及びピリミジン誘導体
DK1981875T3 (da) * 2006-01-19 2014-07-14 Janssen Pharmaceutica Nv Substituerede indolylalkylaminoderivater som inhibitorer af histondeacetylase
JP5255559B2 (ja) * 2006-03-31 2013-08-07 アボット・ラボラトリーズ インダゾール化合物
MX2009004059A (es) 2006-10-23 2009-04-27 Sgx Pharmaceuticals Inc Triazoles biciclicos como moduladores de proteina cinasa.
US20080139531A1 (en) * 2006-12-04 2008-06-12 Alcon Manufacturing Ltd. Use of connective tissue mast cell stabilizers to facilitate ocular surface re-epithelization and wound repair
ME00811B (me) * 2006-12-08 2012-03-20 Novartis Ag JEDINJENJA l KOMPOZICIJE KAO INHIBITORI PROTEIN KINAZE
EP2537830A1 (de) 2006-12-08 2012-12-26 Irm Llc Verbindungen und Zusammensetzungen als Proteinkinase-Inhibitoren
CA2673965A1 (en) * 2006-12-28 2008-07-10 Taisho Pharmaceutical Co., Ltd. Pyrazolopyrimidine compound
WO2008107444A1 (en) 2007-03-07 2008-09-12 Boehringer Ingelheim International Gmbh 9h- purine derivatives and their use in the treatment of proliferative diseases
WO2008124848A1 (en) 2007-04-10 2008-10-16 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN101289449A (zh) * 2007-04-20 2008-10-22 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和应用
WO2008135232A1 (en) * 2007-05-02 2008-11-13 Riccardo Cortese Use and compositions of purine derivatives for the treatment of proliferative disorders
EP2162132A4 (de) * 2007-05-21 2013-01-16 Sgx Pharmaceuticals Inc Heterozyklische kinasemodulatoren
CL2008001540A1 (es) * 2007-05-29 2009-05-22 Sgx Pharmaceuticals Inc Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer.
WO2009026107A1 (en) * 2007-08-17 2009-02-26 Portola Pharmaceuticals, Inc. Protein kinase inhibitors
FR2929851B1 (fr) * 2008-04-09 2012-11-30 Centre Nat Rech Scient Molecules inhibant une voie metabolique impliquant la proteine tyrosine kinase syk et procede d'identification de ces molecules
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
CN102066338A (zh) * 2008-04-22 2011-05-18 波托拉医药品公司 蛋白激酶抑制剂
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
NO2300013T3 (de) 2008-05-21 2018-02-03
US20100029689A1 (en) * 2008-07-02 2010-02-04 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors
WO2010111406A2 (en) * 2009-03-24 2010-09-30 Myriad Pharmaceuticals, Inc. Compounds and therapeutic uses thereof
NZ600673A (en) * 2009-12-17 2013-11-29 Merck Canada Inc Aminopyrimidines as syk inhibitors
MX2012007402A (es) 2009-12-23 2012-08-23 Takeda Pharmaceutical Pirrolidinonas heteroaromaticas fusionadas como inhibidores de tirosina cinasa esplenica (syk).
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
EP2489663A1 (de) 2011-02-16 2012-08-22 Almirall, S.A. Verbindungen als Syk-Kinasehemmer
WO2012151561A1 (en) 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2707357B1 (de) 2011-05-10 2017-01-18 Merck Sharp & Dohme Corp. Pyridylaminopyrimidine als syk-hemmer
BR112013028900A2 (pt) 2011-05-10 2017-01-03 Merck Sharp & Dohe Corp Composto, composição farmacêutica, e, método para o tratamento ou a prevenção de doenças
EP2706852B1 (de) 2011-05-10 2018-08-22 Merck Sharp & Dohme Corp. Bipyridylaminopyridine als syk-hemmer
EP2713737B1 (de) 2011-06-01 2016-04-20 Janus Biotherapeutics, Inc. Neue immunsystemmodulatoren
JP6026525B2 (ja) 2011-06-22 2016-11-16 武田薬品工業株式会社 置換６−アザ−イソインドリン−１−オン誘導体
EP2763975B1 (de) 2011-10-05 2016-04-06 Merck Sharp & Dohme Corp. 3-pyridyl-carboxamidhaltige milztyrosinkinase-(syk)-hemmer
EP2763976B1 (de) 2011-10-05 2016-05-18 Merck Sharp & Dohme Corp. 2-pyridyl-carboxamid-haltige milztyrosinkinase-hemmer
US9006444B2 (en) 2011-10-05 2015-04-14 Merck Sharp & Dohme Corp. Phenyl carboxamide-containing spleen tyrosine kinase (SYK) inhibitors
BR112014012396B1 (pt) 2011-11-23 2020-08-25 Portola Pharmaceuticals, Inc inibidores de pirazina quinase, composição, método in vitro para inibição de quinase syk ou via de transdução de sinal, uso dos referidos inibidores e kit
AR090650A1 (es) * 2012-04-12 2014-11-26 Alcon Res Ltd Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
EP2863913B1 (de) 2012-06-20 2018-09-12 Merck Sharp & Dohme Corp. Imidazolylanaloga als syk-hemmer
WO2013192125A1 (en) 2012-06-20 2013-12-27 Merck Sharp & Dohme Corp. Pyrazolyl derivatives as syk inhibitors
WO2013192098A1 (en) 2012-06-22 2013-12-27 Merck Sharp & Dohme Corp. SUBSTITUTED PYRIDINE SPLEEN TYROSINE KINASE (Syk) INHIBITORS
EP2863915B1 (de) 2012-06-22 2017-12-06 Merck Sharp & Dohme Corp. Substituierte diazin- und triazin-milz-tyrosinkinase-hemmer
US9353066B2 (en) 2012-08-20 2016-05-31 Merck Sharp & Dohme Corp. Substituted phenyl-Spleen Tyrosine Kinase (Syk) inhibitors
US9586931B2 (en) 2012-09-28 2017-03-07 Merck Sharp & Dohme Corp. Triazolyl derivatives as Syk inhibitors
WO2014093191A1 (en) 2012-12-12 2014-06-19 Merck Sharp & Dohme Corp. AMINO-PYRIMIDINE-CONTAINING SPLEEN TYROSINE KINASE (Syk) INHIBITORS
US9598405B2 (en) 2012-12-21 2017-03-21 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyridines as spleen tyrosine kinase inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
WO2014176216A1 (en) 2013-04-26 2014-10-30 Merck Sharp & Dohme Corp. Thiazole-substituted aminopyrimidines as spleen tyrosine kinase inhibitors
US9745295B2 (en) 2013-04-26 2017-08-29 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
CN104418858B (zh) * 2013-08-30 2018-12-11 浙江医药股份有限公司新昌制药厂 2,6-二含氮取代的嘌呤衍生物及其制备方法和其药物组合物与应用
WO2015095444A1 (en) 2013-12-20 2015-06-25 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
EP3083559B1 (de) 2013-12-20 2021-03-10 Merck Sharp & Dohme Corp. Thiazolsubstituierte aminoheteroaryle als milztyrosinkinasehemmer
US9783531B2 (en) 2013-12-20 2017-10-10 Merck Sharp & Dohme Corp. Thiazole-substituted aminoheteroaryls as spleen tyrosine kinase inhibitors
US9775839B2 (en) 2014-03-13 2017-10-03 Merck Sharp & Dohme Corp. 2-pyrazine carboxamides as spleen tyrosine kinase inhibitors
WO2015162518A1 (en) 2014-04-25 2015-10-29 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands
RU2570113C1 (ru) * 2014-12-08 2015-12-10 Федеральное государственное бюджетное учреждение науки Институт органического синтеза им. И.Я. Постовского Уральского отделения Российской академии наук N-(2-ацетамидопурин-6-ил)глицин, обладающий противотуберкулезной активностью
CN107801397B (zh) * 2015-02-13 2021-07-30 达纳－法伯癌症研究所公司 Lrrk2抑制剂及其制备和使用方法
WO2017017571A1 (en) * 2015-07-24 2017-02-02 Glaxo Group Limited Treatment for vitiligo
US10711002B2 (en) 2016-04-21 2020-07-14 The Royal Institution For The Advancement Of Learning/Mcgill University Purine compounds and method for the treatment of cancer
AU2017345736B2 (en) 2016-10-21 2022-04-07 Takeda Pharmaceutical Company Limited TYK2 inhibitors and uses thereof
WO2019076817A1 (en) 2017-10-19 2019-04-25 Bayer Animal Health Gmbh USE OF FUSED HETEROAROMATIC PYRROLIDONES FOR THE TREATMENT AND PREVENTION OF DISEASES IN ANIMALS
EP3814354B1 (de) * 2018-06-22 2023-11-08 The Royal Institution for the Advancement of Learning / McGill University Purinverbindungen und verfahren zur behandlung von krebs
WO2020123675A1 (en) * 2018-12-11 2020-06-18 Duke University Compositions and methods for the treatment of cancer
EP3942045A1 (de) 2019-03-21 2022-01-26 Onxeo Dbait-molekül in kombination mit einem kinaseinhibitor zur behandlung von krebs
AU2020378630A1 (en) 2019-11-08 2022-05-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3529497A1 (de) 1985-08-17 1987-02-26 Boehringer Mannheim Gmbh N(pfeil hoch)6(pfeil hoch)-disubstituierte purinderivate, verfahren zu deren herstellung sowie diese verbindungen enthaltende arzneimittel
EP0626964A1 (de) 1992-02-19 1994-12-07 Pfizer Inc. Heterocyclische verbindungen mit antitumor aktivität
CA2130937A1 (en) 1992-04-03 1993-10-14 Gordon L. Bundy Pharmaceutically active bicyclic-heterocyclic amines
US5550132A (en) 1994-06-22 1996-08-27 University Of North Carolina Hydroxyalkylammonium-pyrimidines or purines and nucleoside derivatives, useful as inhibitors of inflammatory cytokines
JP4004066B2 (ja) * 1995-11-01 2007-11-07 ノバルティス アクチエンゲゼルシャフト プリン誘導体およびその製法
US5866702A (en) * 1996-08-02 1999-02-02 Cv Therapeutics, Incorporation Purine inhibitors of cyclin dependent kinase 2
CA2297967A1 (en) 1997-08-07 1999-02-18 The Regents Of The University Of California Purine inhibitor of protein kinases, g proteins and polymerases
GB9903762D0 (en) * 1999-02-18 1999-04-14 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN1365360A (zh) 2002-08-21
CO5180626A1 (es) 2002-07-30
CA2379560C (en) 2009-09-29
ECSP003589A (es) 2002-02-25
BR0012888A (pt) 2002-04-09
ZA200200783B (en) 2003-04-30
PT1200435E (pt) 2004-02-27
PL354477A1 (en) 2004-01-26
TR200200234T2 (tr) 2002-06-21
MXPA02001102A (es) 2002-08-20
TWI255268B (en) 2006-05-21
PE20010543A1 (es) 2001-05-14
GB9918035D0 (en) 1999-09-29
MY126862A (en) 2006-10-31
WO2001009134A1 (en) 2001-02-08
HUP0201935A2 (hu) 2002-11-28
HK1046679A1 (zh) 2003-01-24
NO20020467L (no) 2002-03-20
KR20020015394A (ko) 2002-02-27
ES2208395T3 (es) 2004-06-16
US6589950B1 (en) 2003-07-08
EP1200435B1 (de) 2003-10-01
KR100485289B1 (ko) 2005-04-27
JP2007217426A (ja) 2007-08-30
CA2379560A1 (en) 2001-02-08
DK1200435T3 (da) 2004-02-02
NZ516667A (en) 2004-05-28
AR029175A1 (es) 2003-06-18
DE60005684D1 (de) 2003-11-06
TW200524932A (en) 2005-08-01
AU767349B2 (en) 2003-11-06
SK1262002A3 (en) 2002-07-02
CN1213047C (zh) 2005-08-03
IL147455A0 (en) 2002-08-14
HUP0201935A3 (en) 2005-02-28
EP1200435A1 (de) 2002-05-02
DE60005684T2 (de) 2004-07-29
CZ2002299A3 (cs) 2002-04-17
SK285730B6 (sk) 2007-07-06
NO20020467D0 (no) 2002-01-29
JP2003506375A (ja) 2003-02-18
AU6567700A (en) 2001-02-19
RU2248977C2 (ru) 2005-03-27
TWI274754B (en) 2007-03-01

Similar Documents

Publication Publication Date Title
ATE251160T1 (de) Purin-derivative inhibitoren der tyrosi-protein kinase syk
NO20033635L (no) Pyrimidinderivater for inhibering av celle-formering
NO20022864L (no) Aminotiazol inhibitorer av syklin uavhengig kinase
DK1319003T3 (da) Xanthin-phosphodiesterase V-inhibitorer
ATE318603T1 (de) Pyrrolotriazin kinasehemmer
ATE256127T1 (de) Betacarbolinderivate als phosphodiesterase- inhibitoren
ID22982A (id) PIRAZOL-PIRAZOL TERSUBSTITUSI SEBAGAI INHIBITOR KINASE p38
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
PT1226136E (pt) Inibidores da tirosina quinase
ATE278690T1 (de) Substituierte pyprolopyridinonderivate als phosphodiesterase-inhibitoren
DE60026861D1 (de) Purin-derivate
IS7599A (is) Heterósýklískir kínasatálmar
DE60002356D1 (de) Purin-derivate
IS6196A (is) Púrín afleiður
NO20022125D0 (no) Pyrrolderivater som inhibitorer for fosfodiesterase VII
DK1226143T3 (da) Imidazopyridinderivater som phosphodiesterase VII-inhibitorer
NO20016201D0 (no) Tienopyrimidiner som fosfodiesteraseinhibitorer
HK1077520A1 (zh) 用作p38促細胞分裂原活化蛋白激酶抑制劑的吲哚類衍生物
NO20022123D0 (no) Osoksazolderivater for anvendelse som inhibitorer for fosfodiesterase VII
DK1222193T3 (da) Imidazolderivater som phosphodiesterase VII-inhibitorer
IDP000027420A (id) Inhibitor-inhibitor kinase pirolotriazin
DK1296981T3 (da) Substituerede pyrrolopyridinonderivater som phosphodiesteraseinhibitorer
SI1483265T1 (sl) Drivati purina kot inhibitoriji kinaze

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1200435

Country of ref document: EP

REN Ceased due to non-payment of the annual fee